Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study

被引：54

作者：

Kwan, P ^{[1
]}

Sills, GJ ^{[1
]}

Kelly, K ^{[1
]}

Butler, E ^{[1
]}

Brodie, MJ ^{[1
]}

机构：

[1] Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland

来源：

EPILEPSY RESEARCH | 2000年 / 42卷 / 2-3期

关键词：

epilepsy; seizures; glutamic acid decarboxylase antibodies; mesial temporal sclerosis; cortical dysplasia;

D O I：

10.1016/S0920-1211(00)00180-7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

There have been anecdotal reports of raised glutamic acid decarboxylase (CAD) autoantibodies in patients with refractory epilepsy. We measured serum GAD autoantibodies in 105 patients with idiopathic or symptomatic epilepsy. There was no significant difference in the absolute titre of GAD autoantibody between patients with controlled and uncontrolled epilepsy. However, four female patients with uncontrolled epilepsy had levels that were over three times above the highest detected in the seizure-free group, three of whom also tested positive for pancreatic islet cell antibodies. Larger scale studies, perhaps comparing different epilepsy syndromes, are required to determine the exact clinical role of GAD autoantibodies in epilepsy. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：191 / 195

页数：5

共 20 条

[1] The $64000 question in diabetes continues... [J].